FDA Grants “Breakthrough Therapy” Status for Gene Therapy to reduce Systolic ... Next Big Future Tweet Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, announced that its lead product candidate, ... FDA grants breakthrough therapy status for Celladon' heart failure treatment ... |
